DV
Dividend Vision

BNTX — BioNTech SE

BioNTech SE (BNTX)

Total return is 562.4% over the past 6.8 years, 370.5 points ahead of SPY at 191.9%. Its deepest 1-year drawdown was 29.7%.

BNTX is a single-stock equity holding in BioNTech SE, a German biotechnology company focused on developing mRNA-based therapeutics and vaccines. As an individual stock rather than a diversified fund, it does not have a regular dividend distribution, expense ratio, or yield profile typical of dividend ETFs. This holding appeals primarily to growth-oriented investors seeking direct exposure to a biotech company rather than income-focused investors.

BNTX key facts

Asset type
Stock
Asset class
Equity
Inception date
10/10/2019
Last close
$93.09
Market cap
$23,384,612,864
Average volume
650531.0
Ex-dividend date
06/02/2022
Payment date
06/17/2022
Beta
1.278
Payout ratio
0.0
Forward P/E
7.0373
EPS
$-7.75